| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
TAK1-IN-4 targets TAK1 (also known as MAP3K7), a serine/threonine kinase that plays a central role in multiple signaling pathways. TAK1 is a key mediator of pro-inflammatory signals, including those from TNF-α, IL-1, and Toll-like receptors. It is involved in the activation of NF-κB and MAPK pathways. By inhibiting TAK1, the compound can modulate inflammatory responses and has potential applications in treating inflammatory diseases and cancer.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for TAK1-IN-4, such as IC50 values, are not provided in the available sources. It is described as a TAK1 inhibitor. Its activity would typically be assessed in kinase inhibition assays measuring the phosphorylation of TAK1 substrates.
|
| ln Vivo |
Specific in vivo activity data for TAK1-IN-4 are not available in the sources. As a TAK1 inhibitor, it would be expected to have effects in animal models of inflammation or cancer. However, no specific studies are described.
|
| Enzyme Assay |
A cell-free assay for TAK1-IN-4 involves measuring its inhibition of TAK1 kinase activity. Recombinant TAK1 is incubated with a peptide substrate and ATP in the presence of varying concentrations of the compound. The incorporation of phosphate into the substrate is measured, and the IC50 is calculated. Specific protocols and IC50 values are not detailed in the available sources.
|
| Cell Assay |
Cellular assays for TAK1-IN-4 would typically involve assessing its effects on TAK1-dependent signaling pathways. Cells are treated with the compound and stimulated with inflammatory cytokines. The phosphorylation of downstream targets, such as IKK and JNK, is measured by Western blotting. The compound's ability to inhibit NF-κB activation and cytokine production can also be assessed.
|
| Animal Protocol |
In vivo animal experiments for TAK1-IN-4 are not described in the available sources. As a research compound, it could be evaluated in animal models of inflammatory diseases or cancer. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
TAK1-IN-4 has a molecular formula of C18H17N3O3 and a molecular weight of 323.35 g/mol. It is soluble in DMSO at 83.33 mg/mL. For storage, the powder should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for TAK1-IN-4 are not provided in the available sources. As a research compound, it is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
TAK1-IN-4 (CAS: 1570374-32-1) is a TAK1 inhibitor. It is also known as Compound 14. The compound is used in research to study the role of TAK1 in signaling pathways related to inflammation, immunity, and cancer. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C18H17N3O3
|
|---|---|
| Molecular Weight |
323.345884084702
|
| Exact Mass |
323.126
|
| CAS # |
1570374-32-1
|
| PubChem CID |
137796976
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
470
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=CC=C(C(=O)O)C=1)NC1=NC2C=CC=CC=2N1CCC
|
| InChi Key |
OWYWEJQTFNMMSF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H17N3O3/c1-2-10-21-15-9-4-3-8-14(15)19-18(21)20-16(22)12-6-5-7-13(11-12)17(23)24/h3-9,11H,2,10H2,1H3,(H,23,24)(H,19,20,22)
|
| Chemical Name |
3-[(1-propylbenzimidazol-2-yl)carbamoyl]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~257.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0926 mL | 15.4631 mL | 30.9262 mL | |
| 5 mM | 0.6185 mL | 3.0926 mL | 6.1852 mL | |
| 10 mM | 0.3093 mL | 1.5463 mL | 3.0926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
